JP4919575B2 - ファルネシルトランスフェラーゼ阻害性１，２−環付加キノリン鏡像異性体 - Google Patents

ファルネシルトランスフェラーゼ阻害性１，２−環付加キノリン鏡像異性体 Download PDF

Info

Publication number
JP4919575B2
JP4919575B2 JP2002504258A JP2002504258A JP4919575B2 JP 4919575 B2 JP4919575 B2 JP 4919575B2 JP 2002504258 A JP2002504258 A JP 2002504258A JP 2002504258 A JP2002504258 A JP 2002504258A JP 4919575 B2 JP4919575 B2 JP 4919575B2
Authority
JP
Japan
Prior art keywords
chlorophenyl
pharmaceutically acceptable
quinazoline
tetrazolo
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002504258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501153A (ja
JP2004501153A5 (https=
Inventor
ブネ，マルク・ガストン
アンジボー，パトリク・ルネ
エンド，デイビツド・ウイリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of JP2004501153A publication Critical patent/JP2004501153A/ja
Publication of JP2004501153A5 publication Critical patent/JP2004501153A5/ja
Application granted granted Critical
Publication of JP4919575B2 publication Critical patent/JP4919575B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2002504258A 2000-06-22 2001-06-13 ファルネシルトランスフェラーゼ阻害性１，２−環付加キノリン鏡像異性体 Expired - Lifetime JP4919575B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00202181.4 2000-06-22
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (3)

Publication Number Publication Date
JP2004501153A JP2004501153A (ja) 2004-01-15
JP2004501153A5 JP2004501153A5 (https=) 2008-07-17
JP4919575B2 true JP4919575B2 (ja) 2012-04-18

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002504258A Expired - Lifetime JP4919575B2 (ja) 2000-06-22 2001-06-13 ファルネシルトランスフェラーゼ阻害性１，２−環付加キノリン鏡像異性体

Country Status (33)

Country Link
US (3) US20030114471A1 (https=)
EP (1) EP1296984B1 (https=)
JP (1) JP4919575B2 (https=)
KR (2) KR100846370B1 (https=)
CN (1) CN1207296C (https=)
AR (1) AR030704A1 (https=)
AT (1) ATE294804T1 (https=)
AU (3) AU2001263962B2 (https=)
BG (1) BG65894B1 (https=)
BR (1) BRPI0111743B8 (https=)
CA (1) CA2410232C (https=)
CZ (1) CZ295278B6 (https=)
DE (1) DE60110592T2 (https=)
EA (1) EA005065B1 (https=)
EE (1) EE04966B1 (https=)
EG (1) EG24180A (https=)
ES (1) ES2241830T3 (https=)
HR (1) HRP20020989B1 (https=)
HU (1) HU229095B1 (https=)
IL (2) IL153560A0 (https=)
IS (1) IS2596B (https=)
JO (1) JO2361B1 (https=)
MX (1) MXPA02012845A (https=)
MY (1) MY127734A (https=)
NO (1) NO324494B1 (https=)
NZ (1) NZ522481A (https=)
PA (1) PA8519501A1 (https=)
PL (1) PL209521B1 (https=)
SA (1) SA01220349B1 (https=)
SK (1) SK285699B6 (https=)
UA (1) UA73572C2 (https=)
WO (1) WO2001098302A1 (https=)
ZA (1) ZA200210305B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
DE60307616T2 (de) 2002-04-15 2007-10-04 Janssen Pharmaceutica N.V. Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
HUE044698T2 (hu) 2015-08-17 2019-11-28 Kura Oncology Inc Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー， インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
JP2000507955A (ja) 1996-04-03 2000-06-27 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
RU2205831C2 (ru) * 1997-04-25 2003-06-10 Янссен Фармацевтика Н.В. Хиназолиноны, ингибирующие фарнезилтрансферазу
CN100525766C (zh) 1997-06-02 2009-08-12 詹森药业有限公司 用作平滑肌细胞增殖抑制剂的（咪唑-5-基）甲基-2-喹啉酮衍生物
PL193464B1 (pl) * 1998-07-06 2007-02-28 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
TR200101343T2 (tr) * 1998-08-27 2001-09-21 Pfizer Products Inc. Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
DE69923849T2 (de) * 1998-08-27 2006-01-12 Pfizer Products Inc., Groton Quinolin-2-on-derivate verwendbar als antikrebsmittel
DK1140935T3 (da) * 1998-12-23 2003-09-01 Janssen Pharmaceutica Nv 1,2-anellerede quinolinderivater
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
SK11002001A3 (sk) * 1999-02-11 2002-05-09 Pfizer Products Inc. Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
ATE375794T1 (de) * 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
WO2002024686A2 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives

Also Published As

Publication number Publication date
IS6590A (is) 2002-10-25
HUP0300872A2 (hu) 2003-07-28
HK1058363A1 (en) 2004-05-14
BR0111743A (pt) 2003-07-08
EP1296984B1 (en) 2005-05-04
US20080114009A1 (en) 2008-05-15
NO20026032D0 (no) 2002-12-16
CA2410232A1 (en) 2001-12-27
EP1296984A1 (en) 2003-04-02
HRP20020989B1 (hr) 2011-05-31
AU2001263962B2 (en) 2006-07-20
MXPA02012845A (es) 2003-05-15
CZ2003114A3 (cs) 2003-05-14
AU6396201A (en) 2002-01-02
KR100846370B1 (ko) 2008-07-15
AR030704A1 (es) 2003-09-03
ATE294804T1 (de) 2005-05-15
CZ295278B6 (cs) 2005-06-15
AU2006220405A1 (en) 2006-10-12
HUP0300872A3 (en) 2004-11-29
KR20030009463A (ko) 2003-01-29
US8318753B2 (en) 2012-11-27
MY127734A (en) 2006-12-29
CN1437601A (zh) 2003-08-20
CN1207296C (zh) 2005-06-22
BRPI0111743B1 (pt) 2019-03-26
IS2596B (is) 2010-03-15
US20070259902A1 (en) 2007-11-08
BRPI0111743B8 (pt) 2021-05-25
KR20070121847A (ko) 2007-12-27
PL358918A1 (en) 2004-08-23
JP2004501153A (ja) 2004-01-15
DE60110592T2 (de) 2006-01-19
EA005065B1 (ru) 2004-10-28
NZ522481A (en) 2004-09-24
DE60110592D1 (de) 2005-06-09
EG24180A (en) 2008-09-28
BG107310A (bg) 2003-07-31
HU229095B1 (en) 2013-07-29
EA200300048A1 (ru) 2003-04-24
SK502003A3 (en) 2003-05-02
PL209521B1 (pl) 2011-09-30
KR100831940B1 (ko) 2008-05-23
PA8519501A1 (es) 2002-08-29
CA2410232C (en) 2008-10-07
AU2006220405B2 (en) 2009-05-21
EE200200695A (et) 2004-06-15
BG65894B1 (bg) 2010-04-30
IL153560A0 (en) 2003-07-06
ES2241830T3 (es) 2005-11-01
NO324494B1 (no) 2007-10-29
JO2361B1 (en) 2006-12-12
ZA200210305B (en) 2004-03-19
NO20026032L (no) 2002-12-16
HRP20020989A2 (en) 2005-02-28
US8329714B2 (en) 2012-12-11
WO2001098302A1 (en) 2001-12-27
UA73572C2 (en) 2005-08-15
SK285699B6 (sk) 2007-06-07
IL153560A (en) 2011-06-30
US20030114471A1 (en) 2003-06-19
EE04966B1 (et) 2008-02-15
SA01220349B1 (ar) 2007-01-23

Similar Documents

Publication Publication Date Title
JP4974438B2 (ja) ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体
JP4911866B2 (ja) ファルネシルトランスフェラーゼ阻害剤としてのファルネシルトランスフェラーゼを阻害するキノリンおよびキナゾリン誘導体
JP4974439B2 (ja) ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
US8318753B2 (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
JP2005523909A (ja) ファルネシルトランスフェラーゼインヒビターとして使用するためのベンジルイミダゾリル置換２−キノリンおよびキナゾリン誘導体
AU2001263962A1 (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
JP4348080B2 (ja) ファルネシルトランスフェラーゼを阻害するベンゾ複素環誘導体
JP4537710B2 (ja) ファルネシルトランスフェラーゼ阻害剤としての炭素連結トリアゾールで置換されている１，８−アネル化キノリン誘導体
JP4384505B2 (ja) ファルネシルトランスフェラーゼを阻害する炭素連結イミダゾールもしくはトリアゾール置換三環状キナゾリン誘導体
HK1058363B (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120124

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120131

R150 Certificate of patent or registration of utility model

Ref document number: 4919575

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150210

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term